Mir-139 Regulates Autophagy in Prostate Cancer Cells Through Beclin-1 and mTOR Signaling Proteins.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 07 10 2020
revised: 19 10 2020
accepted: 23 10 2020
entrez: 8 12 2020
pubmed: 9 12 2020
medline: 17 12 2020
Statut: ppublish

Résumé

We previously identified a panel of five miRNAs (including miR-139) associated with biochemical recurrence and metastasis in prostate cancer patients. We examined miR-139 transfected PC3, DU145 and LNCaP cells by morphology as well as by cell-based assays, confocal microscopy and immunoblotting. We found that treatment of prostate cancer cells with miR-139 resulted in phenotypic changes characteristic of autophagic cells. MiR-139 increased the autophagy-related conversion of the microtubule-associated protein light chain 3 (LC3-I to LC3-II) that was specifically inhibited by the miR-139 antagomir. The upregulation of LC3 II was further confirmed by confocal microscopy. miR-139 regulated activation of both mTOR and Beclin1 the two important autophagy-related molecules. We found that upon miR-139 treatment, the cargo adaptor protein p62 which is degraded during autophagy, accumulates. These results suggest that miR-139 is inducing autophagic flux blockade leading to apoptosis in prostate cancer cells through the mTOR and Beclin-1 proteins.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
We previously identified a panel of five miRNAs (including miR-139) associated with biochemical recurrence and metastasis in prostate cancer patients.
MATERIALS AND METHODS METHODS
We examined miR-139 transfected PC3, DU145 and LNCaP cells by morphology as well as by cell-based assays, confocal microscopy and immunoblotting.
RESULTS RESULTS
We found that treatment of prostate cancer cells with miR-139 resulted in phenotypic changes characteristic of autophagic cells. MiR-139 increased the autophagy-related conversion of the microtubule-associated protein light chain 3 (LC3-I to LC3-II) that was specifically inhibited by the miR-139 antagomir. The upregulation of LC3 II was further confirmed by confocal microscopy. miR-139 regulated activation of both mTOR and Beclin1 the two important autophagy-related molecules. We found that upon miR-139 treatment, the cargo adaptor protein p62 which is degraded during autophagy, accumulates.
CONCLUSION CONCLUSIONS
These results suggest that miR-139 is inducing autophagic flux blockade leading to apoptosis in prostate cancer cells through the mTOR and Beclin-1 proteins.

Identifiants

pubmed: 33288559
pii: 40/12/6649
doi: 10.21873/anticanres.14689
doi:

Substances chimiques

Beclin-1 0
MIRN139 microRNA, human 0
MicroRNAs 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6649-6663

Informations de copyright

Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Robert K Nam (RK)

Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Tania Benatar (T)

Platform Biological Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.

Yutaka Amemiya (Y)

Genomics Core Facility, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.

Christopher Sherman (C)

Department of Laboratory Medicine and Pathobiology, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.

Arun Seth (A)

Platform Biological Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; arun.seth@utoronto.ca.
Genomics Core Facility, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada arun.seth@utoronto.ca.
Department of Laboratory Medicine and Pathobiology, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; arun.seth@utoronto.ca.
Faculty of Dentistry, University of Toronto, Toronto, ON, Canada arun.seth@utoronto.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH